Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -48.75%871.14M | -9.83%2.86B | 9.16%1.7B | 9.22%3.17B | -16.56%1.56B | 85.91%2.91B | 98.32%1.87B | 82.05%1.56B | 249.99%941M | -23.70%858.42M |
| Operating income | -48.75%871.14M | -9.83%2.86B | 9.16%1.7B | 9.22%3.17B | -16.56%1.56B | 85.91%2.91B | 98.32%1.87B | 82.05%1.56B | 249.99%941M | -23.70%858.42M |
| Cost of sales | 25.72%-786.74M | -1.19%-2.01B | -8.25%-1.06B | -9.13%-1.99B | 8.89%-978.53M | -92.01%-1.82B | -110.16%-1.07B | -72.49%-947.97M | -201.71%-511.02M | 14.89%-549.58M |
| Operating expenses | 25.72%-786.74M | -1.19%-2.01B | -8.25%-1.06B | -9.13%-1.99B | 8.89%-978.53M | -92.01%-1.82B | -110.16%-1.07B | -72.49%-947.97M | -201.71%-511.02M | 14.89%-549.58M |
| Gross profit | -86.83%84.4M | -28.29%851.17M | 10.71%640.71M | 9.38%1.19B | -26.95%578.73M | 76.51%1.09B | 84.26%792.28M | 99.05%614.75M | 332.16%429.98M | -35.56%308.84M |
| Administrative expenses | 12.87%-130.79M | 8.02%-303.47M | 10.04%-150.11M | -38.72%-329.94M | -87.91%-166.87M | -45.76%-237.85M | -25.27%-88.8M | -3.61%-163.18M | 3.06%-70.89M | 6.91%-157.49M |
| Revaluation surplus | -126.69%-44.03M | ---- | -49.44%164.95M | 416.27%959.33M | 177.94%326.27M | -263.95%-303.32M | -98.58%-418.62M | -80.64%185.02M | 70.50%-210.81M | -18.69%955.69M |
| -Changes in the fair value of derivative financial instruments | -231.51%-216.93M | ---- | -49.44%164.95M | 416.27%959.33M | 177.94%326.27M | -263.95%-303.32M | -98.58%-418.62M | -80.64%185.02M | 70.50%-210.81M | -18.69%955.69M |
| -Changes in the fair value of other assets | --172.9M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Impairment and provision | 40.40%-354.06M | -219.13%-1.29B | 10.42%-594.06M | 179.64%1.08B | -20.76%-663.14M | -225.81%-1.36B | -348.84%-549.14M | -137.29%-418.08M | 340.89%220.68M | 88.87%1.12B |
| -Impairment of intangible assets | 45.39%-30.89M | -194.91%-118.75M | -1.40%-56.56M | 197.58%125.12M | -2.53%-55.78M | -227.04%-128.23M | -308.08%-54.41M | -129.66%-39.21M | 386.02%26.15M | 90.73%132.19M |
| -Impairment of property, machinery and equipment | 40.41%-322.6M | -221.86%-1.18B | 10.46%-541.4M | 178.37%965.06M | -22.47%-604.64M | -226.50%-1.23B | -353.38%-493.69M | -138.19%-377.17M | 336.22%194.84M | 89.06%987.71M |
| -Other impairment is provision | -114.52%-567K | 146.01%2.48M | 243.71%3.91M | -119.74%-5.4M | -161.85%-2.72M | -44.44%-2.46M | -230.57%-1.04M | -226.09%-1.7M | -2,062.50%-314K | -29.96%1.35M |
| Special items of operating profit | 1,770.34%50.23M | 753.66%203.67M | 55.09%-3.01M | -164.97%-31.16M | 2.97%-6.7M | 169.55%47.96M | -1.63%-6.9M | -78.72%17.79M | -123.11%-6.79M | -65.56%83.61M |
| Operating profit | -774.13%-394.24M | -118.85%-540.94M | -14.36%58.48M | 472.59%2.87B | 125.18%68.29M | -425.97%-770.25M | -174.88%-271.19M | -89.78%236.3M | 148.26%362.18M | -0.43%2.31B |
| Financing cost | 19.83%-276.94M | 0.32%-653.8M | -1.85%-345.43M | -9.46%-655.86M | -15.56%-339.16M | -10.28%-599.21M | -10.51%-293.49M | -10.61%-543.37M | -5.15%-265.57M | 38.65%-491.23M |
| Earning before tax | -133.90%-671.19M | -153.96%-1.19B | -5.94%-286.95M | 261.67%2.21B | 52.03%-270.87M | -345.98%-1.37B | -684.51%-564.68M | -116.87%-307.07M | 109.63%96.61M | 19.69%1.82B |
| Tax | 55.78%-68.97M | 66.07%-181.92M | 43.49%-155.96M | -129.46%-536.12M | -52.24%-275.97M | -456.52%-233.64M | -275.42%-181.27M | -64.15%-41.98M | -948.99%-48.29M | 67.72%-25.58M |
| After-tax profit from continuing operations | -67.11%-740.15M | -182.04%-1.38B | 19.01%-442.91M | 204.67%1.68B | 26.69%-546.84M | -359.27%-1.6B | -1,643.70%-745.95M | -119.44%-349.05M | 104.80%48.32M | 24.49%1.8B |
| Earning after tax | -67.11%-740.15M | -182.04%-1.38B | 19.01%-442.91M | 204.67%1.68B | 26.69%-546.84M | -359.27%-1.6B | -1,643.70%-745.95M | -119.44%-349.05M | 104.80%48.32M | 24.49%1.8B |
| Profit attributable to shareholders | -67.11%-740.15M | -182.04%-1.38B | 19.01%-442.91M | 204.67%1.68B | 26.69%-546.84M | -359.27%-1.6B | -1,643.70%-745.95M | -119.44%-349.05M | 104.80%48.32M | 24.49%1.8B |
| Basic earnings per share | -67.23%-3.93 | -182.06%-7.32 | 19.24%-2.35 | 204.69%8.92 | 26.70%-2.91 | -358.06%-8.52 | -1,626.92%-3.97 | -119.50%-1.86 | 104.85%0.26 | 24.54%9.54 |
| Diluted earnings per share | -67.23%-3.93 | -182.06%-7.32 | 19.24%-2.35 | 204.69%8.92 | 26.70%-2.91 | -358.06%-8.52 | -3,153.85%-3.97 | -602.70%-1.86 | 102.43%0.13 | 146.67%0.37 |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Auditor | -- | -- | -- | -- | -- | Ernst & Young | -- | Ernst & Young | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.